Rheumatoid Arthritis (RA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Reasons to buy the ‘Rheumatoid Arthritis (RA)’ marketed and pipeline drugs assessment report:
- Get a comprehensive overview of the rheumatoid arthritis market including disease epidemiology, treatment guidelines, clinical trials, deals, and an assessment of marketed and pipeline drugs.
- Get an insight into MoA, RoA, and molecule types for the leading marketed and pipeline drugs in RA.
- Assess the pricing and reimbursement of rheumatoid arthritis marketed and pipeline drugs.
- Get a detailed assessment of the clinical trials taking place within the rheumatoid arthritis market by phase, status, and geography.
- Examine the trends, deals, and future market catalysts shaping and driving the rheumatoid arthritis market.
How is our ‘Rheumatoid Arthritis’ marketed and pipeline drugs assessment report unique from other reports in the market?
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global rheumatoid arthritis market in the future.
We recommend this valuable source of information to anyone involved in:
- Pharmaceutical/Biotech/Drug Manufacturing Industries (Big Pharma, Small Biotech, Start-ups, etc.),
- Pharmaceutical Industry Suppliers (e.g., Consulting Companies, CMOs, CDMOs, CROs, Technology Vendors)
- Consulting and Professional Services (e.g., Investment Companies, Investment Banks, Equity Companies, etc.)
- Pharma Manufacturers/Distributors (Innovative, Biotech, Generics, Biosimilars, Rare/Orphan Disease)
- Financial Institutions (Investors in Pharma/Biotech, Pricing Consultancies)/Parallel Trade Organizations
- Healthcare Organizations (HTA Bodies, Reimbursement Groups and Payers, Government Healthcare Organizations)
- Clinical Research Organizations (CROs)
To Get a Snapshot of the Rheumatoid Arthritis (RA) Report
Rheumatoid Arthritis Marketed and Pipeline Drugs Report Overview
RA is a chronic autoimmune condition characterized by inflammation affecting the joints, erosion of bones and cartilage, and joint deformities. This condition arises from an immune response in which the body’s immune system erroneously targets its healthy cells, particularly the synovial membrane lining the joints, leading to inflammation.
| Key Mechanisms of Action (Marketed) | · Receptor Agonist
· Enzyme Inhibitor · Biological Factor Inhibitor · Protein & Peptide Inhibitor · Receptor Antagonist |
| Key Molecule Types (Marketed) | · Small Molecule
· Biologic · Polymer |
| Key Routes of Administration (Marketed) | · Oral
· Injection · Topical · Suppository · Inhalational |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
The Rheumatoid Arthritis Marketed and Pipeline Drugs Market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, and pricing and reimbursement of therapy in major countries. Furthermore, the report analyzes late-to-mid-stage pipeline products with Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) for Rheumatoid Arthritis.
The report also provides actionable insights into the clinical and commercial landscapes of Rheumatoid Arthritis drugs, M&A deals, and market catalysts. These critical data will help you develop and design your in-licensing and out-licensing strategies. Furthermore, identify companies with the most robust pipelines to create smart business goals.
| Key Mechanisms of Action (Pipeline) | · Enzyme Inhibitor
· Biological Factor Inhibitor · Receptor Antagonist · Protein & Peptide Inhibitor · Receptor Agonist · Antigen Inhibitor |
| Key Molecule Types (Pipeline) | · Biologic
· Small Molecule · Oligonucleotide · Polymer |
| Key Routes of Administration (Pipeline) | · Injection
· Oral · Topical · Inhalational |
| Top Sponsors (Marketed and Pipeline Drugs) | · Pfizer Inc.
· Eli Lilly & Co. · AbbVie Inc. · Bristol-Meyers Squibb Co. · Astellas Pharma Inc. · Amgen Inc. · Sanofi |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Rheumatoid Arthritis Marketed Drugs Market Segmentation by Mechanisms of Action
The key MoA of the marketed drugs for rheumatoid arthritis include receptor agonist, enzyme inhibitor, biological factor inhibitor, protein & peptide inhibitor, and receptor antagonist among others. Most of the marketed drugs followed receptor agonist MoA in 2023 in the rheumatoid arthritis market.
Rheumatoid Arthritis Marketed Drugs Market Analysis by Mechanisms of Action, 2023 (%)
Buy the Full Report to Know More about the MoA of Rheumatoid Arthritis Marketed Drugs
Rheumatoid Arthritis Marketed Drugs Market Segmentation by Routes of Administration
The key RoA of rheumatoid arthritis marketed drugs include oral, injection, topical, suppository, and inhalational. Most marketed drugs that were available for rheumatoid arthritis were oral therapies, followed by injectables.
Rheumatoid Arthritis Marketed Drugs Market Analysis by Routes of Administration, 2023 (%)
Buy the Full Report to Know More about the RoA of Rheumatoid Arthritis Marketed Drugs
Rheumatoid Arthritis Marketed Drugs Market Segmentation by Molecule Types
In 2023, the leading molecule type for rheumatoid arthritis marketed drugs was small molecule, followed by biologic, and polymer.
Rheumatoid Arthritis Marketed Drugs Market Analysis by Molecule Types, 2023 (%)
Buy the Full Report to Know More about the Molecule Types of Rheumatoid Arthritis Marketed Drugs
Rheumatoid Arthritis Pipeline Drugs Market Segmentation by Mechanisms of Action
The key MoA of the drugs in the rheumatoid arthritis pipeline mainly include enzyme inhibitor, biological factor inhibitor, receptor antagonist, protein & peptide inhibitor, receptor agonist, and antigen inhibitor among others. Most of the pipeline drugs undergoing development for RA followed enzyme inhibitor MoA in 2023.
Rheumatoid Arthritis Pipeline Drugs Market Analysis by Mechanisms of Action, 2023 (%)
Buy the Full Report to Know More about the MoA of Rheumatoid Arthritis Pipeline Drugs
Rheumatoid Arthritis Pipeline Drugs Market Segmentation by Routes of Administration
The key RoA of the drugs in the rheumatoid arthritis pipeline mainly include injection, oral, topical, and inhalational. In 2023, most pipeline drugs that were under development for rheumatoid arthritis were injection therapies.
Rheumatoid Arthritis Pipeline Drugs Market Analysis by Routes of Administration, 2023 (%)
Buy the Full Report to Know More about the RoA of Rheumatoid Arthritis Pipeline Drugs
Rheumatoid Arthritis Pipeline Drugs Market Segmentation by Molecule Types
In 2023, the leading molecule type for rheumatoid arthritis pipeline drugs was biologic, followed by small molecule. A few of the RA drugs currently in development are also oligonucleotide and polymer type.
Rheumatoid Arthritis Pipeline Drugs Market Analysis by Molecule Types, 2023 (%)
Buy the Full Report to Know More about the Molecule Types of Rheumatoid Arthritis Pipeline Drugs
Rheumatoid Arthritis Marketed and Pipeline Drugs Market – Competitive Landscape
A few of the top sponsors in Rheumatoid Arthritis marketed and pipeline drugs market are Pfizer Inc., Eli Lilly & Co., AbbVie Inc., Bristol-Meyers Squibb Co., Astellas Pharma Inc., Amgen Inc., and Sanofi among others. Pfizer Inc. sponsored the highest number of trials in 2023. Roche conducted the highest number of Phase III trials, while the highest number of Phase II trials was sponsored by AbbVie.
Rheumatoid Arthritis Marketed and Pipeline Drugs Market Analysis by Sponsors, 2023 (%)
Buy Full Report for More Sponsor Insights into the Rheumatoid Arthritis Marketed and Pipeline Drugs Market
Segments Covered in the Report
Rheumatoid Arthritis Marketed Drugs Mechanisms of Action Outlook (Number of Drugs, 2023)
- Receptor Agonist
- Enzyme Inhibitor
- Biological Factor Inhibitor
- Protein & Peptide Inhibitor
- Receptor Antagonist
Rheumatoid Arthritis Marketed Drugs Molecule Types Outlook (Number of Drugs, 2023)
- Biologic
- Small Molecule
- Oligonucleotide
- Polymer
Rheumatoid Arthritis Pipeline Drugs Mechanisms of Action Outlook (Number of Drugs, 2023)
- Enzyme Inhibitor
- Biological Factor Inhibitor
- Receptor Antagonist
- Protein & Peptide Inhibitor
- Receptor Agonist
- Antigen Inhibitor
Rheumatoid Arthritis Pipeline Drugs Molecule Types Outlook (Number of Drugs, 2023)
- Biologic
- Small Molecule
- Oligonucleotide
- Polymer
Scope
The key components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Table of Contents
Frequently asked questions
-
Which was the leading MoA for rheumatoid arthritis marketed drugs in 2023?
Most of the drugs followed receptor agonist MoA in 2023 in the rheumatoid arthritis drugs market.
-
Which was the leading molecule type for rheumatoid arthritis marketed drugs in 2023?
In 2023, more than 90% of marketed drugs for RA were small molecules.
-
Which was the leading MoA for rheumatoid arthritis pipeline drugs in 2023?
Most of the drugs followed receptor antagonists MoA in 2023 in the rheumatoid arthritis drugs market.
-
Which was the leading molecule type for rheumatoid arthritis pipeline drugs in 2023?
In 2023, most of the drugs in development for rheumatoid arthritis were biologics.
-
Who are the top sponsors in the rheumatoid arthritis marketed and pipeline drugs market?
A few of the top sponsors in the rheumatoid arthritis marketed and pipeline drugs market are Pfizer Inc., Eli Lilly & Co., AbbVie Inc., Bristol-Meyers Squibb Co., Astellas Pharma Inc., Amgen Inc., and Sanofi among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Sample Report
Rheumatoid Arthritis (RA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Rheumatoid Arthritis reports